(Q28285948)

English

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

scientific article

In more languages

Statements

scholarly article

0 references

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance (English)

0 references

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

0 references

Narayan Raj Bhattarai

5

0 references

Manu Vanaerschot

8

0 references

Saskia Decuypere

9

0 references

Marleen Boelaert

14

0 references

object named as

Keshav Rai

4

0 references

object named as

Murari Lal Das

11

0 references

7

object named as

Jos H Beijnen

0 references

author name string

Suman Rijal

1

0 references

Bart Ostyn

2

0 references

Thomas P C Dorlo

6

0 references

Subodh S Dhakal

10

0 references

Prahlad Karki

12

0 references

Rupa Singh

13

0 references

Jean-Claude Dujardin

15

0 references

language of work or name

0 references

publication date

June 2013

0 references

Clinical Infectious Diseases

0 references

56

0 references

11

0 references

1530-8

0 references

Leishmaniasis worldwide and global estimates of its incidence

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Oral miltefosine for Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

A policy for leishmaniasis with respect to the prevention and control of drug resistance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Leishmania resistance to miltefosine associated with genetic marker

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIT102

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28285948&oldid=1983936677"